A Study of Flt3-Ligand Levels in Sjögrens Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Göteborg University
Sponsor:
Information provided by (Responsible Party):
Göteborg University
ClinicalTrials.gov Identifier:
NCT01470638
First received: November 9, 2011
Last updated: June 25, 2014
Last verified: June 2014
  Purpose

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.


Condition
Sjogrens Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases

Resource links provided by NLM:


Further study details as provided by Göteborg University:

Primary Outcome Measures:
  • Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome [ Time Frame: June 2009 - June 2015 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum, cerebrospinal fluid


Estimated Enrollment: 50
Study Start Date: June 2009
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Detailed Description:

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The rheumatology clinic at Sahlgrenska University hospital, Gothenburg, Sweden

Criteria

Inclusion Criteria:

  • fulfill the ACR-criteria for primary Sjogrens syndrome,
  • age above 18 years old

Exclusion Criteria:

  • other CNS-disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01470638

Contacts
Contact: Mats Dehlin, PhD-student +46-31-3424173 mats.dehlin@vgregion.se

Locations
Sweden
Dept of Rheumatology, Sahlgrenska University Hospital Recruiting
Gothenburg, Sweden, 413 46
Contact: Mats Dehlin, PhD student    +46-31-3424173    mats.dehlin@vgregion.se   
Principal Investigator: Mats Dehlin, MD         
Sponsors and Collaborators
Göteborg University
  More Information

No publications provided

Responsible Party: Göteborg University
ClinicalTrials.gov Identifier: NCT01470638     History of Changes
Other Study ID Numbers: Flt3-L SS
Study First Received: November 9, 2011
Last Updated: June 25, 2014
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Göteborg University:
Flt3-L
CSF

Additional relevant MeSH terms:
Sjogren's Syndrome
Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 23, 2014